© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 1, 54-61,
January 5, 2000
© 2000 Oxford University Press
REPORTS |
Hematologic Disorders Associated With Primary Mediastinal Nonseminomatous Germ Cell Tumors
Affiliations of authors: J. T. Hartmann, L. Kanz, C. Bokemeyer, Tuebingen University Medical Center II, Germany; C. R. Nichols, Oregon Health Sciences University, Portland; J.-P. Droz, Centre Léon-Berard, Groupe d'Etude des Tumeurs Uro-geniales, Lyon, France; A. Horwich, The Royal Marsden Hospital, Sutton, U.K.; A. Gerl, Klinikum Großhadern, Munich, Germany; S. D. Fossa, The Norwegian Radium Hospital, Oslo, Norway; J. Beyer, Virchow Klinikum, Berlin, Germany; J. Pont, Kaiser-Franz-Josef Spital, Vienna, Austria; K. Fizazi, Institut Gustave-Roussy, Villejuif, France; L. Einhorn, Indiana University, Indianapolis.
Correspondence to: Carsten Bokemeyer, M.D., Department of Hematology/Oncology/Immunology, UKL-University Medical Center II, Eberhard-Karls-University, Otfried-Mueller-Str. 10, 72076 Tuebingen, Germany (e-mail: carsten.bokemeyer{at}med.uni-tuebingen.de).
BACKGROUND. The association between primary germ cell tumors of the mediastinum (the space between the lung pleura that contains the heart and other chest viscera) and hematologic malignancies has been described by retrospective analysis of patients treated at individual clinical centers. To better characterize the risk of hematologic disorders in patients with extragonadal germ cell tumors and to describe the clinical and biologic features of the disorders, we studied an unselected population in a large, international, multicenter database. METHODS. Six hundred thirty-five patients treated at 11 centers in the United States and Europe from 1975 through 1996 were evaluated retrospectively. RESULTS. A hematologic disorder was observed in 17 patients with germ cell tumors. All cases developed among the 287 patients with primary mediastinal nonseminomatous germ cell tumors, giving an incidence rate in this group of 2.0% (95% confidence interval [CI] = 1.1%-3.1%) per year over a median follow-up time of 3 years. The risk of developing hematologic disorders was statistically significantly increased in patients with primary mediastinal nonseminomatous germ cell tumors in comparison with the age-matched general population (standardized incidence ratio = 250; 95% CI = 140-405). The median time to onset of hematologic neoplasia was 6 months (range, 0-47 months), and the median survival after diagnosis of the hematologic disorder was 5 months (range, 0-16 months) (two-sided P<.0001, comparing survival from the time of diagnosis of the germ cell tumor of patients with and without hematologic disorders). CONCLUSION. In our study, approximately one in 17 patients with primary mediastinal nonseminomatous germ cell tumors was affected by a hematologic disorder, whereas no cases were seen among 334 patients with other extragonadal germ cell tumors. The hematologic disorder had a statistically significant impact on prognosis, with none of the 17 reported patients surviving for more than 2 years.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. R. Brahmanday, G. Gheorghe, I. A. Jaiyesimi, A. Orazi, R. Zekman, R. Parikh, S. M. Wills, and L. H. Einhorn Primary Mediastinal Germ Cell Tumor Evolving Into an Extramedullary Acute Megakaryoblastic Leukemia Causing Cord Compression J. Clin. Oncol., October 1, 2008; 26(28): 4686 - 4688. [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Kang, Y. T. Kim, S.-H. Jheon, S.-w. Sung, and J. H. Kim Surgical Treatment of Malignant Mediastinal Nonseminomatous Germ Cell Tumor Ann. Thorac. Surg., February 1, 2008; 85(2): 379 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Hartmann, T. Gauler, B. Metzner, A. Gerl, J. Casper, O. Rick, M. Horger, J. Schleicher, G. Derigs, R. Mayer-Steinacker, et al. Phase I/II Study of Sequential Dose-Intensified Ifosfamide, Cisplatin, and Etoposide Plus Paclitaxel As Induction Chemotherapy for Poor Prognosis Germ Cell Tumors by the German Testicular Cancer Study Group J. Clin. Oncol., December 20, 2007; 25(36): 5742 - 5747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Marina, W. B. London, A. L. Frazier, S. Lauer, F. Rescorla, B. Cushing, M. H. Malogolowkin, R. P. Castleberry, R. B. Womer, and T. Olson Prognostic Factors in Children With Extragonadal Malignant Germ Cell Tumors: A Pediatric Intergroup Study J. Clin. Oncol., June 1, 2006; 24(16): 2544 - 2548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Song, Y. H. Ko, and G. Ahn Mediastinal Germ Cell Tumor Associated with Histiocytic Sarcoma of Spleen: Case Report of an Unusual Association International Journal of Surgical Pathology, July 1, 2005; 13(3): 299 - 303. [Abstract] [PDF]
|
|
|
|
 |
|
 U. De Giorgi, T. Demirer, H. Wandt, C. Taverna, W. Siegert, M. Bornhauser, T. Kozak, G. Papiani, M. Ballardini, G. Rosti, et al. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience Ann. Onc., January 1, 2005; 16(1): 146 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Rogers, T. A. Olson, J. W. Cullen, D. F. Billmire, N. Marina, F. Rescorla, M. M. Davis, W. B. London, S. J. Lauer, R. H. Giller, et al. Treatment of Children and Adolescents With Stage II Testicular and Stages I and II Ovarian Malignant Germ Cell Tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891 J. Clin. Oncol., September 1, 2004; 22(17): 3563 - 3569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Cushing, R. Giller, J. W. Cullen, N. M. Marina, S. J. Lauer, T. A. Olson, P. C. Rogers, P. Colombani, F. Rescorla, D. F. Billmire, et al. Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882 J. Clin. Oncol., July 1, 2004; 22(13): 2691 - 2700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Hartmann, C. R. Nichols, J.-P. Droz, A. Horwich, A. Gerl, S. D. Fossa, J. Beyer, J. Pont, L. Kanz, L. Einhorn, et al. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors Ann. Onc., July 1, 2002; 13(7): 1017 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bokemeyer, C. R. Nichols, J.-P. Droz, H.-J. Schmoll, A. Horwich, A. Gerl, S. D. Fossa, J. Beyer, J. Pont, L. Kanz, et al. Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis J. Clin. Oncol., April 1, 2002; 20(7): 1864 - 1873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Omezzine, C. Khouatra, S. Larive, G. Freyer, S. Isaac-Pinet, L. Geriniere, J.-P. Droz, and P.-J. Souquet Rhabdomyosarcoma arising in mediastinal teratoma in an adult man: a case report Ann. Onc., February 20, 2002; 13(2): 323 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Hartmann, S. D. Fossa, C. R. Nichols, J.-P. Droz, A. Horwich, A. Gerl, J. Beyer, J. Pont, K. Fizazi, H. Hecker, et al. Incidence of Metachronous Testicular Cancer in Patients With Extragonadal Germ Cell Tumors J Natl Cancer Inst, November 21, 2001; 93(22): 1733 - 1738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Hartmann, L. Einhorn, C. R. Nichols, J.-P. Droz, A. Horwich, A. Gerl, S. D. Fossa, J. Beyer, J. Pont, H.-J. Schmoll, et al. Second-Line Chemotherapy in Patients With Relapsed Extragonadal Nonseminomatous Germ Cell Tumors: Results of an International Multicenter Analysis J. Clin. Oncol., March 15, 2001; 19(6): 1641 - 1648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vuky, M. Bains, J. Bacik, G. Higgins, D. F. Bajorin, M. Mazumdar, G. J. Bosl, and R. J. Motzer Role of Postchemotherapy Adjunctive Surgery in the Management of Patients With Nonseminoma Arising From the Mediastinum J. Clin. Oncol., February 1, 2001; 19(3): 682 - 688. [Abstract] [Full Text] [PDF]
|
|